




2025
(Pharmacy)

GNIPST BULLETIN

Volume-3, Issue- 2



**GURU NANAK INSTITUTE OF PHARMACEUTICAL
SCIENCE AND TECHNOLOGY**


157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



Table of Contents

- 01** Message from Director and Principal
- 02** Recent Researches
- 03** New Drug Approvals
- 04** Clinical Trial News
- 05** Disease Outbreak News
- 06** Campus News
- 07** Special Page and Game time





MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt greetings to our academic community and well-wishers on the auspicious occasion of the 79th Independence Day of our nation.

This day is a solemn reminder of the sacrifices made by countless freedom fighters and visionaries who gifted us the invaluable legacy of freedom.

It calls upon us to uphold the ideals of unity, integrity, and progress that form the foundation of our great nation.

At GNIPST, we remain committed to nurturing inquisitive minds, fostering innovation, and shaping future leaders in Pharmaceutical Sciences who will contribute to a healthier, stronger, and self-reliant India. Let us draw inspiration from our glorious past and step forward with renewed determination to serve society and the nation with dedication and excellence.

Wishing you and your families good health, peace, prosperity, and success on this proud occasion of Independence Day.


Jai Hind!

Prof. (Dr.) Abhijit Sengupta



MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and best wishes to our students, faculty, staff, alumni, and valued partners on the proud occasion of the 79th Independence Day of our nation. May this day inspire us all with peace, prosperity, good health, and a renewed sense of commitment to the ideals of freedom, unity, and nation-building.



At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we remain steadfast in our pursuit of academic excellence, inclusive growth, and service to society. Since our inception in 2005, GNIPST has emerged as a distinguished center of pharmacy education—recognized by the Pharmacy Council of India (PCI) and honored as the first pharmacy institution in the region to achieve both NAAC and NBA accreditations. Our recent achievement of securing the 74th rank in NIRF 2024 stands as a testament to our commitment to quality education and professional advancement.

As we celebrate this historic day, we reaffirm our mission to nurture intellectual curiosity, foster innovation, and prepare our students to be leaders in pharmaceutical sciences—guided by values of integrity, responsibility, and dedication to the nation. True independence lies not only in freedom but also in empowering ourselves through knowledge, innovation, and service to humanity.

Let us move forward together with courage, passion, and a shared vision of a healthier, stronger, and self-reliant India.

Wishing you continued success, fulfillment, and pride as we celebrate our nation's Independence.

Jai Hind!

Prof. (Dr.) Lopamudra Datta





RECENT RESEARCHES



Kenya achieves elimination of human African trypanosomiasis or sleeping sickness as a public health problem

MORE INFO

www.who.int/

WHO outlines recommendations to protect infants against RSV – respiratory syncytial virus

MORE INFO

www.who.int/

Cholera – Multi-country with a focus on countries experiencing current surges

MORE INFO

www.who.int/

The World Health Organization (WHO) has validated Kenya as having eliminated human African trypanosomiasis (HAT) or sleeping sickness as a public health problem, making it the tenth country to reach this important milestone. HAT is the second neglected tropical disease (NTD) to be eliminated in Kenya: the country was certified free of Guinea worm disease in 2018.

On 4 August 2025, Israel notified WHO of a circulating vaccine-derived poliovirus type 1 (cVDPV1) outbreak. Between February and July 2025, nine genetically linked virus isolates were found in environmental samples from seven sites, mainly in Jerusalem and the Central Region. No human cases of paralytic polio have been reported. Israel discontinued routine use of the bivalent oral polio vaccine in March 2025 but continues using inactivated polio vaccine (IPV) as part of the country's routine immunization schedule. WHO and partners of the Global Polio Eradication Initiative are supporting national and subnational authorities. WHO assesses the risk of international spread of this cVDPV1 outbreak in Israel as low, due to strong overall immunity, surveillance, and response systems. However, the virus is circulating in under-vaccinated, vaccine-sceptic communities with ties to similar groups abroad, posing a potential risk for further spread.

The global cholera situation continues to deteriorate, driven by conflict and poverty, posing a significant public health challenge across multiple WHO regions. Between 1 January and 17 August 2025, a total of 409 222 cholera/Acute Watery Diarrhoea (AWD) cases and 4738 deaths were reported globally, from 31 countries, with six of the 31 countries reporting case fatality rates above 1%, indicating serious gaps in case management and delayed access to care. Cholera is resurging in a number of countries, including some that had not reported substantial case numbers in years, like Chad and the Republic of Congo, while other countries, such as the Democratic Republic of the Congo, South Sudan, and Sudan, are experiencing outbreaks that are continuing from 2024, with significant geographic expansion. This complicates containment efforts and strains fragile health systems. Conflict, mass displacement, disasters from natural hazards, and climate change have intensified outbreaks, particularly in rural and flood-affected areas, where poor infrastructure and limited healthcare access delay treatment. These cross-border factors have made cholera outbreaks increasingly complex and harder to control. Safe drinking water, sanitation and hygiene are the only long-term and sustainable solutions to ending this cholera emergency and preventing future ones. Given the scale, severity, and interconnected nature of these outbreaks, the risk of further spread within and between countries is considered very high.

FDA



NEW DRUG APPROVALS

JULY, 2025

Zegfrovy (sunvozertinib) Tablets

- Company: Dizal
- Date of Approval: July 2, 2025
- Treatment for: Non Small Cell Lung Cancer



Kirsty (insulin aspart-xjhz) Injection

- Company: Biocon Biologics Inc.
- Date of Approval: July 15, 2025
- Treatment for: Diabetes Mellitus

Anzupgo (delgocitinib) Topical Cream

- Company: LEO Pharma Inc.
- Date of Approval: July 23, 2025
- Treatment for: Chronic Hand Eczema

Vizz (aceclidine) Ophthalmic Solution – formerly LNZ100

- Company: LENZ Therapeutics, Inc.
- Date of Approval: July 31, 2025
- Treatment for: Presbyopia

Ekterly (sebetralstat) Tablets

- Company: KalVista Pharmaceuticals, Inc.
- Date of Approval: July 3, 2025
- Treatment for: Hereditary Angioedema

Vostally (ramipril) Oral Solution

- Company: Rosemont Pharmaceuticals Inc.
- Date of Approval: July 23, 2025
- Treatment for: High Blood Pressure, Cardiovascular Risk Reduction

Sephience (sepiapterin) Oral Powder

- Company: PTC Therapeutics, Inc.
- Date of Approval: July 28, 2025
- Treatment for: Phenylketonuria



<https://www.drugs.com/newdrugs.html>



CLINICAL TRIAL NEWS


01.

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

SAN FRANCISCO and BOSTON, July 07, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, today announced positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777, a potential best-in-class anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis (AD).

02.

FDA Grants Fast Track Designation for TRE-515 in Combination with Radiation Therapy for the Treatment of Metastatic Castration Resistant Prostate Cancer

Los Angeles, July 9, 2025 — Trethera Corporation ("Trethera"), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its novel drug, TRE-515, in the treatment of prostate cancer. TRE-515 is currently in phase 1 clinical trials for solid tumors.

03.

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

JNOVATO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its Biologics License Application (BLA) for UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA).

04.

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1.

OSAKA, Japan and CAMBRIDGE, Massachusetts, July 14, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of ovporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist, in narcolepsy type 1 (NT1). NT1 is caused by the loss of orexin-producing neurons in the brain. Orexin agonists are designed to address this underlying orexin deficiency. For the first time, this mechanism of action has been validated in Phase 3 studies demonstrating significant improvement across a broad range of symptoms. These results reinforce the potential of ovporexton to transform the standard of care.

05.

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

SAN DIEGO and SUZHOU, China, July 15, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced outcomes from its Type B meeting with the United States Food and Drug Administration (FDA). Adagene has received written feedback from the FDA on its clinical development plan to evaluate muzastotug (ADG126) in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab: 200 mg, Q3W) in patients with microsatellite stable colorectal cancer (MSS CRC).

06.

Johnson & Johnson Receives U.S. FDA Priority Review for TAR-200 NDA in High-Risk Non-Muscle Invasive Bladder Cancer

RARITAN, N.J., JULY 17, 2025 – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200, an intravesical gemcitabine releasing system, for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.

07.

Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma

SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for CLD-201 (SuperNova), the company's allogeneic adipose stem-cell loaded oncolytic virus for the treatment of soft tissue sarcoma.

MORE INFORMATION ➔

https://www.drugs.com/clinical_trials_archive/january-2025.html



DISEASE OUTBREAK NEWS (DONS)


July, 2025

Nipah virus infection - India

6 August, 2025

Situation at a glance

Between 17 May and 12 July 2025, the Information and Public Relations Department, Government of Kerala informed through a series of official press releases about four confirmed cases, including two deaths, due to Nipah virus (NiV) infection in two districts of Kerala State. NiV infection is a bat-borne disease transmitted to humans through infected animals (such as bats or pigs), contaminated food or, less commonly, through close contact with infected individuals. Since 1998 NiV outbreaks have been reported in Bangladesh, India, Malaysia, the Philippines, and Singapore. In India, NiV infections have occurred multiple times since 2001 with outbreaks in West Bengal State in 2001 and 2007, and in Kerala State regularly since 2018. Since 2018, Kerala has reported a total of nine NiV outbreaks. While the state has a strong healthcare system and improved infection control measures since 2023, it is advisable to maintain strong preparedness and surveillance efforts while ensuring continued care for patients. At the same time, States that may be at risk should be encouraged to continue strengthen their detection systems and response capacities. With no licensed vaccine or treatment available, public health efforts should focus on raising awareness of risk factors and promoting preventive measures to reduce exposure to the virus, and on early case detection supported by adequate intensive supportive care. Currently, the risk of international disease spread is considered low. There is no evidence of human-to-human transmission of NiV internationally in this event.




**MORE
INFO**

<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON573>

Circulating vaccine-derived poliovirus type 1 - Israel

20 August, 2025



Situation at a glance

On 4 August 2025, Israel notified WHO of a circulating vaccine-derived poliovirus type 1 (cVDPV1) outbreak. Between February and July 2025, nine genetically linked virus isolates were found in environmental samples from seven sites, mainly in Jerusalem and the Central Region. No human cases of paralytic polio have been reported. Israel discontinued routine use of the bivalent oral polio vaccine in March 2025 but continues using inactivated polio vaccine (IPV) as part of the country's routine immunization schedule. WHO and partners of the Global Polio Eradication Initiative are supporting national and subnational authorities. WHO assesses the risk of international spread of this cVDPV1 outbreak in Israel as low, due to strong overall immunity, surveillance, and response systems. However, the virus is circulating in under-vaccinated, vaccine-sceptic communities with ties to similar groups abroad, posing a potential risk for further spread.

**MORE
INFO**

<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON566>

CAMPUS NEWS



1. Kirtan and Ardas: Kirtan and Ardas was organized on 14th August 2025 at the GNIPST campus, marking the beginning of the week-long 20th Foundation Day celebrations. The event created a serene and spiritual atmosphere, bringing together students, faculty, and staff to seek blessings for peace, prosperity, and continued success of the institution.



3. Extempore Program: An Extempore Program titled "Thought On Spot" was organized on 14th August 2025 at the GNIPST campus to commemorate 20 glorious years of the institution. The event encouraged spontaneity, confidence, and eloquence among participants, making it a truly inspiring and engaging experience.



4. Cultural Program: GNIPST students and teachers came together to organize a vibrant Jamming Session on 19th August. The lively performances filled the atmosphere with music, joy, and togetherness, making the grand finale truly memorable.



2. Painting Competition: Sit and Draw Painting Competition followed by an Exhibition was organized on 14th August 2025 at the GNIPST campus. The event beautifully showcased the talent and creativity of participants, filling the campus with colors, imagination, and artistic expression.



5. Annapurna Seva: Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), in collaboration with International Vedanta Society, organized ANNAPURNA SEVA – Sacred Service Shared With Love on the occasion of the week-long 20th Foundation Day celebrations. The program was held at Khelaghar Charitable Trust, Madhyamgram, Badu, West Bengal – 700128 on 20th August 2025 from 11 AM onwards, spreading love, compassion, and care through selfless service.



6. Motivational Talk: Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST) organized a Motivational Talk by the Brahmakumaris titled "Appreciate the Self" on 18th August 2025 at the GNIPST Auditorium, as part of the week-long 20th Foundation Day celebrations. The session inspired students, faculty, and staff to embrace positivity, self-value, and inner strength, creating an atmosphere of peace and motivation.



HAPPY *Independence Day* INDIA

15TH AUGUST

Independence Day, celebrated every year on 15th August, is one of the most important national festivals of India. On this day in 1947, India finally broke free from nearly 200 years of British colonial rule after long struggles, countless movements, and immense sacrifices. Great leaders and freedom fighters like Mahatma Gandhi, Subhas Chandra Bose, Jawaharlal Nehru, Sardar Vallabhbhai Patel, Bhagat Singh, Rani Lakshmibai, and many others devoted their lives to the cause of independence. Their courage and determination inspired millions of Indians to unite against oppression. The event not only marked the end of foreign domination but also the birth of a sovereign, democratic nation. Since then, this day has been observed with great pride and patriotism across the country.


Significance of Independence Day

1. **Historical Importance** – It commemorates the sacrifices of freedom fighters who struggled for India's independence.
2. **Symbol of Unity** – The day brings together people of different religions, languages, and regions under one national identity.
3. **Patriotic Spirit** – Citizens express love and respect for the nation through flag hoisting, cultural programs, and parades.
4. **Reminder of Responsibilities** – Independence Day not only celebrates freedom but also reminds every citizen of their duty to contribute to nation-building.
5. **Global Recognition** – The day reflects India's journey from colonial rule to becoming the world's largest democracy.


Inspiration for Youth – It motivates young generations to uphold values of justice, equality, and progress.



GNIPST GAME TIME



Cross Word (Ph-7)



Across

2. The hard covering that protects seeds
3. The body's controller that coordinates activities and functions
4. The process by which plants make their own food using sunlight
5. The part of the plant that absorbs sunlight and helps in photosynthesis
6. The tiny units that make up all living things
7. A part of a plant that grows down into the soil to take in water and nutrients
8. The study of living organisms

Down

1. The process of a caterpillar turning into a butterfly
2. The substance that gives plants their green color and helps in photosynthesis
3. The pumping organ responsible for circulating blood in the body

Stay tuned for to the next edition for a shout out to fastest correct answers!

Submit your answer



or

CLICK
HERE

Celebrating the Achievers!

Volume -3, Issue -1



Prianshu Kundu
B.Pharm, 5th Semester

Editorial Board

Editor- in- Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamura Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major
Recruiters



**Latest
news**



www.gnipst.ac.in

www.facebook.com

www.instagram.com



www.linkedin.com

www.youtube.com

api.whatsapp.com